Cannabinoid CB1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo

摘要: Intravenous administration of the cannabinoid CB1 receptor agonists (R-(+)-[2,3-Dihydro-5-methyl-3[morpholinyl)methyl]-pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate), WIN 55,212-2 (10, 37.5, 75 and 150 μg/kg), ((6aR)-trans-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol), HU 210 (1 4 μg/kg) dose-dependently increased acetylcholine release in dialysates from prefrontal cortex hippocampus freely moving rats. Administration antagonist {N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3carboxamide}HCl, SR 141716A, at a dose that per se did not affect basal (2.5 prevented increase by (150 μg/kg i.v.) or (4 both areas. These data demonstrate that, low i.v. doses, synthetic agonists, stimulate cortical hippocampal release.